Biochemical markers of muscle damage and high serum concentration of creatine kinase in patients on statin therapy

• Published in: Biomarkers in medicine 2019-06, Vol.13 (8), p.619-626
• Main Authors: Nogueira, Adriana Ar, Strunz, Célia Mc, Takada, Julio Y, Mansur, Antonio P
• Format: Article
• Language: English
• Subjects: Automation; Biochemical markers; Biomarkers; Biomarkers - blood; Calcium-binding protein; carbonic anhydrase III; Carbonic anhydrases; Cardiology; Cholesterol; CK; CK-MB; Clinical medicine; Creatine; Creatine kinase; Creatine Kinase - blood; Diabetes; Enzymes; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Inflammatory diseases; Laboratories; Lipids; Male; Marathons; Middle Aged; Muscle pain; Muscular Diseases - blood; Muscular Diseases - chemically induced; Muscular dystrophy; Musculoskeletal diseases; Musculoskeletal system; myalgia; myopathy; myositis; Simvastatin; statin; Statins; Studies; Triglycerides; Troponin; Working groups
• ISSN: 1752-0363; 1752-0371
• DOI: 10.2217/bmm-2018-0379

Some patients experience statin-associated muscle symptoms (SAMS) and elevated serum concentrations of CK. The relationship between SAMS and biomarkers of muscle damage was examined. We analyzed 359 consecutive patients taking statins with high CK values. Muscle-related symptoms and biochemical variables, including CK, MB isoenzyme of creatine kinase (CK-MB), troponin and carbonic anhydrase type III were evaluated. SAMS was reported by 181 (50.4%) patients and they had greater BMI (p = 0.021) and a trend toward higher CK-MB values (p = 0.064). The use of simvastatin (OR: 2.24; 95% CI: 1.47–3.42), CK-MB (OR: 1.59; 95% CI: 1.02–2.49) and BMI (OR: 1.06; 95% CI: 1.01–1.10) were independent variables for SAMS. Simvastatin use, BMI and CK-MB were independent markers of SAMS.